LOS ANGELES--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company with products for the treatment of Xerostomia, dermatological conditions, and acute respiratory diseases, announced today that Andrew Shales, the Company’s Chief Operating Officer and Alan Roberts, Chief Scientific Officer, have terminated their pre-arranged stock trading plans effective immediately. The plans were adopted in accordance with guidelines specified under Securities and Exchange Commission (SEC) Rule 10b5-1. All transactions completed pursuant to the plan were publicly disclosed through Form 144 and Form 4 filings with the SEC.
